BCG 백신 세계 시장은 2024년 1억 4,556만 달러에 달할 것으로 예상되며, 예측 기간 동안 2030년까지 CAGR 5.90%의 괄목할만한 성장이 예상됩니다.
세계 BCG(Bacillus Calmette-Guerin) 백신 시장은 주로 결핵에 대한 최전방 방어 수단으로 공중보건 분야에서 중요한 역할을 하고 있습니다. BCG 백신은 풍부한 역사와 광범위한 사용으로 인해 결핵과의 싸움에서 중요한 도구로 남아 있습니다. 역사적으로 BCG 백신은 20세기 초에 개발되어 결핵에 대한 최초의 성공적인 백신으로 개발되었습니다. 이후 전 세계 수백만 명에게 접종되어 역사상 가장 널리 사용되는 백신 중 하나가 되었습니다. 결핵은 주로 폐를 침범하는 전염성 세균 감염으로, 특히 의료 자원에 대한 접근성이 제한된 지역에서는 세계 보건의 큰 도전이 되고 있습니다.
| 시장 개요 | |
|---|---|
| 예측 기간 | 2026-2030년 |
| 시장 규모 : 2024년 | 1억 4,556만 달러 |
| 시장 규모 : 2030년 | 2억 365만 달러 |
| CAGR : 2025-2030년 | 5.90% |
| 급성장 부문 | 병원 |
| 최대 시장 | 북미 |
세계 BCG 백신 시장의 가장 큰 특징 중 하나는 많은 국가의 예방접종 프로그램에 BCG 백신이 포함되어 있다는 점입니다. 정부 주도의 노력과 의무화로 인해 전 세계 인구의 상당수가 BCG 백신을 접종하고 있으며, 그 중 상당수는 영아에게 출생 시 접종하고 있습니다. 이러한 조기 예방접종은 결핵을 예방하고, 특히 어린이의 중증화 위험을 감소시키는 매우 중요한 예방 수단으로 자리 잡았습니다. 결핵 예방에 대한 전통적인 역할 외에도 현재 진행 중인 연구 개발로 인해 BCG 백신의 응용 가능성이 확대되고 있습니다. 예를 들어, 모체 예방접종은 호흡기질환 등 결핵 이외의 다양한 감염성 질환에 대한 방어력을 산모와 영아 모두에게 제공하는 수단으로 검토되고 있습니다.
개발도상국 및 저개발국에서의 결핵 유병률 증가 추세
공급망 혼란
새로운 결핵균주
Global BCG Vaccines Market was valued at USD 145.56 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.90% through 2030. The global BCG (Bacillus Calmette-Guerin) vaccine market plays a crucial role in the realm of public health, primarily as a frontline defense against tuberculosis (TB). With its rich history and widespread usage, the BCG vaccine remains a vital tool in the global fight against TB. Historically, the BCG vaccine was developed in the early 20th century as the first successful vaccine against TB. Since then, it has been administered to millions of individuals worldwide, making it one of the most widely used vaccines in history. TB, a contagious bacterial infection that primarily affects the lungs, continues to pose a significant global health challenge, particularly in regions with limited access to healthcare resources.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 145.56 Million |
| Market Size 2030 | USD 203.65 Million |
| CAGR 2025-2030 | 5.90% |
| Fastest Growing Segment | Hospitals |
| Largest Market | North America |
One of the key features of the global BCG vaccine market is its inclusion in the immunization programs of many countries. Government-led initiatives and mandates ensure that a substantial portion of the world's population receives the BCG vaccine, often as a birth dose to infants. This early vaccination serves as a crucial preventive measure, offering protection against TB and reducing the risk of severe forms of the disease, particularly in children. In addition to its traditional role in TB prevention, ongoing research and development efforts are expanding the potential applications of the BCG vaccine. Maternal immunization, for example, is being explored as a means to provide both mothers and infants with protection against various infections beyond TB, such as respiratory illnesses.
Key Market Drivers
Increasing Prevalence of Tuberculosis in Developing and under-developed countries
The increasing prevalence of tuberculosis (TB) in developing and underdeveloped countries is a significant driver for the growth of the Bacillus Calmette-Guerin (BCG) vaccine market. For instance, in February 2022, the Ministry of Health and Family Welfare, Government of India, published the "India TB Report 2022." The report highlighted that pediatric tuberculosis remains a significant concern, contributing to approximately 31% of the global TB burden. As a result, the increasing BCG vaccination rate among children is expected to drive higher immunization coverage within the target population. This growing emphasis on BCG vaccination for pediatric TB prevention is anticipated to boost market expansion, supporting efforts to combat tuberculosis more effectively. BCG is a widely used vaccine for the prevention of tuberculosis, and its demand is directly linked to the TB burden in these regions. Here's how the rising TB prevalence contributes to the expansion of the BCG vaccine market: Developing and underdeveloped countries often face higher TB incidence rates due to various factors such as overcrowding, limited access to healthcare, and weakened immune systems among their populations. TB remains a critical public health issue in these regions, making vaccination a crucial strategy for prevention.
Key Market Challenges
Supply chain disruptions
Supply chain disruptions have emerged as a significant challenge for the BCG (Bacillus Calmette-Guerin) vaccine market, impacting the production, distribution, and availability of this critical immunization tool. These disruptions, often stemming from various global factors, have far-reaching consequences for the global efforts to combat tuberculosis (TB) through BCG vaccination. The manufacturing of vaccines like BCG requires a complex supply chain, including the procurement of specific raw materials. Disruptions in the availability of these materials, often due to factors like trade restrictions, natural disasters, or geopolitical tensions, can hinder vaccine production.
The BCG vaccine is produced in select facilities and then distributed globally. Interruptions in transportation networks, such as those caused by the COVID-19 pandemic, can lead to delays in the delivery of vaccines to their intended destinations. These delays can impact vaccination programs and contribute to vaccine shortages. BCG vaccines, like many other vaccines, require strict temperature control throughout the supply chain to maintain their efficacy. Any interruptions or failures in the cold chain, whether due to equipment malfunctions or logistical challenges, can render vaccines ineffective and result in wastage. Ensuring an adequate supply of BCG vaccines relies on the capacity of manufacturing facilities. Disruptions caused by issues such as equipment breakdowns or regulatory obstacles can limit the production volume, leading to supply shortages. Political tensions and trade disputes can affect the movement of vaccines and their components across borders. Export restrictions and tariffs can disrupt the flow of vaccines, exacerbating supply chain challenges.
Key Market Trends
Emerging TB strains
Emerging strains of tuberculosis (TB) have become a concerning trend in recent years, posing a significant challenge to TB control efforts and the Bacillus Calmette-Guerin (BCG) vaccine market. Several factors contribute to the emergence of new TB strains, which are increasingly drug-resistant and harder to treat: The overuse and misuse of antibiotics have led to the development of drug-resistant TB strains. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are particularly worrisome. These strains do not respond to first-line TB drugs, making treatment more complex, lengthy, and expensive.
In an interconnected world with increased global travel and population mobility, TB strains can easily cross borders. Infected individuals may carry drug-resistant TB strains with them, introducing these strains to new regions and populations. Immune-compromised individuals, such as those living with HIV/AIDS, are more susceptible to TB and its drug-resistant forms. This population provides fertile ground for the emergence and spread of TB strains that are more resistant to treatment. Weakened TB control programs in some regions may contribute to the persistence and spread of TB. Inadequate diagnosis, treatment, and infection control measures can allow drug-resistant strains to flourish. TB is a genetically diverse bacterium, and its strains can vary in virulence and resistance. The BCG vaccine, derived from a specific strain, may offer limited protection against some of these diverse TB strains. Advancements in genomics and molecular epidemiology have improved our ability to track and analyze TB strains. Researchers can now identify and characterize emerging strains more effectively, enabling targeted responses and treatment strategies.
In this report, the Global BCG Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the BCG Vaccines Market.
Global BCG Vaccines market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: